Evidence map›Paper›PMID 31256366›Full record

ArticleDrugs & aging2019

Patient-Associated Characteristics Influencing the Risk for Non-Persistence with Statins in Older Patients with Peripheral Arterial Disease.

Martin Wawruch, Gejza Wimmer, Jan Murin, Martina Paduchova, Tomas Tesar, Lubica Hlinkova, Peter Slavkovsky, Lubomira Fabryova, Emma Aarnio

Abstract read
PubMed Publisher
In one paragraph

Article in Drugs & aging, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Statins and Peripheral Arterial Disease: A Narrative Review.Frontiers in cardiovascular medicine · 2021
    Review
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Martin WawruchInstitute of Pharmacology and Clinical Pharmacology, Faculty of Medicine, Comenius University, Sasinkova 4, 811 08, Bratislava, Slovakia. martin.wawruch@gmail.com.ORCID 0000-0001-7672-1574
Gejza WimmerInstitute of Measurement Science, Slovak Academy of Sciences, Bratislava, Slovakia.
Jan Murin1st Department of Internal Medicine, Faculty of Medicine, Comenius University, Bratislava, Slovakia.
Martina PaduchovaDepartment of Angiology, Health Centre, Trnava, Slovakia.
Tomas TesarDepartment of Organisation and Management of Pharmacy, Faculty of Pharmacy, Comenius University, Odbojarov 10, 832 32, Bratislava, Slovakia. tesar@fpharm.uniba.sk.
Lubica HlinkovaGeneral Health Insurance Company, Bratislava, Slovakia.
Peter SlavkovskyInstitute of Pathophysiology, Faculty of Medicine, Comenius University, Bratislava, Slovakia.
Lubomira FabryovaDepartment of Diabetes and Metabolic Disorders, MetabolKLINIK, Bratislava, Slovakia.
Emma AarnioInstitute of Biomedicine, University of Turku, Turku, Finland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND AND

objectivesSecondary prevention of peripheral arterial disease includes administration of statins regardless of the patient's serum cholesterol level. Our study aimed to identify patient-associated risk factors for statin non-persistence and comparison of the explanatory power of models based on clusters of patient-associated characteristics.

methodsOur study cohort (n = 8330) was assembled from the database of the largest health insurance provider in the Slovak Republic. Statin users aged ≥ 65 years in whom peripheral arterial disease was diagnosed during 2012 were included. Patients were followed for 5 years; those with a treatment gap period of at least 6 months without statin prescription were classified as "non-persistent". The risk factors for non-persistence were identified within six models (sociodemographic, cardiovascular events, comorbid conditions, statin-related characteristics, cardiovascular co-medication and full model) using Cox regression. The explanatory power of models was assessed using Harrell's C-index.

resultsAt the end of the follow-up, 35.7% of patients were found to be non-persistent. The full model had the highest explanatory power (C = 0.632). Female sex, atorvastatin and rosuvastatin as initially administered statins, being a new statin user and an increasing co-payment were associated with an increased risk for non-persistence. Increasing age, history of ischaemic stroke, diabetes mellitus, general practitioner as index prescriber, increasing overall number of medications and co-administration of certain cardiovascular co-medications were associated with a lower likelihood for non-persistence.

conclusionsPatients identified as high risk for non-persistence require special attention aimed at the improvement of their persistence with statin treatment.

Indexed as

Drug MonitoringAgedCohort StudiesDatabases, FactualFemaleFollow-Up StudiesHumansHydroxymethylglutaryl-CoA Reductase InhibitorsMalePeripheral Arterial DiseaseRiskSecondary PreventionHydroxymethylglutaryl-CoA Reductase Inhibitors

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.